January 23, 2023

Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), manufactured by the biotechnology company BeiGene, which is a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA reported that the most common adverse reactions seen with zanubrutinib were a decrease in neutrophil count, upper respiratory tract infection, decrease in platelet count, hemorrhage, and musculoskeletal pain.

Read more…


Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail Clients: Contact your Client Relations Manager